甘氨酸,N-[[2-[(二乙氧基氧膦基)甲基]苯基]甲基]-,甲基酯 | 140151-61-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 甘氨酸,N-[[2-[(二乙氧基氧膦基)甲基]苯基]甲基]-,甲基酯
• 英文名称: methyl N-<<2-<(diethylphosphinyl)methyl>phenyl>methyl>glycinate
• 英文别名: methyl N-[[2[(diethoxyphosphinyl)methyl]phenyl]methyl]glycinate；Methyl N[[2[(diethoxyphosphinyl)methyl]phenyl]methyl]glycinate；methyl 2-[[2-(diethoxyphosphorylmethyl)phenyl]methylamino]acetate
• CAS: 140151-61-7
• 化学式: C₁₅H₂₄NO₅P
• 分子量: 329.333
• InChiKey: GUPBKKXSSBAPHL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  22
• 可旋转键数：
  11
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  73.9
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  甘氨酸,N-[[2-[(二乙氧基氧膦基)甲基]苯基]甲基]-,甲基酯 以 盐酸 为溶剂， 生成 N-[[2-(phosphonomethyl)phenyl]methyl]glycine, hydrochloride
  参考文献：
  名称：

  N-substituted .alpha.-amino acids and derivatives thereof having

  摘要：

  N-取代的α-氨基酸及其衍生物被描述，以及用于制备和药物组合物的方法，这些方法在选择性阻断哺乳动物的N-甲基-D-天门冬氨酸(NMDA)兴奋性氨基酸受体方面是有用的，在治疗脑血管疾病如脑梗塞或脑梗塞、脑动脉痉挛、低血糖、心脏骤停、癫痫状态和脑外伤以及治疗精神分裂症、癫痫、神经退行性疾病、阿尔茨海默病或亨廷顿病方面也有用，并可作为外科手术中的麻醉剂，其中存在有限的脑血管损伤风险。

  公开号：

  US05179085A1
• 作为产物：
  描述：

  diethyl [[2-(bromomethyl)phenyl]methyl]phosphonate 、 甘氨酸甲酯盐酸盐 在 水 、 氯仿 、 magnesium sulfate 、 silica gel 、 甲醇 作用下， 以 甲醇 、 三乙胺 为溶剂， 反应 19.0h， 生成 甘氨酸,N-[[2-[(二乙氧基氧膦基)甲基]苯基]甲基]-,甲基酯
  参考文献：
  名称：

  N-substituted .alpha.-amino acids and derivatives thereof having

  摘要：

  本文介绍了N-取代的α-氨基酸及其衍生物，以及制备方法和药物组成物，这些物质在哺乳动物中选择性地阻断N-甲基-D-天门冬氨酸（NMDA）兴奋性氨基酸受体方面有用，也可用于治疗脑血管疾病，如由栓塞性或出血性中风引起的脑缺血或脑梗死、脑血管痉挛、低血糖、心脏停跳、持续性癫痫状态和脑外伤，以及治疗精神分裂症、癫痫、神经退行性疾病、阿尔茨海默病或亨廷顿病，并且还可作为麻醉剂用于存在有限脑血管损伤风险的外科手术中。

  公开号：

  US05179085A1

文献信息

• N-substituted .alpha.-amino acids and derivatives thereof having
  申请人：Warner-Lambert Company

  公开号：US05179085A1

  公开（公告）日：1993-01-12

  N-substituted .alpha.-amino acids and derivatives thereof are described, as well as methods for the preparation and pharmaceutical composition of same, which are useful in selectively blocking the N-methyl-D-aspartate (NMDA) excitatory amino acid receptors in mammals and also are useful in treating cerebrovascular disorders such as cerebral ischemia or cerebral infarction resulting from thromboembolic or hemorrhagic stroke, cerebral vasospasm, hypoglycemia, cardiac arrest, status epilepticus and cerebral trauma as well as for treating schizophrenia, epilepsy, neurodegenerative disorders, Alzheimer's disease or Huntington's disease and also additionally useful as anesthetics in surgical procedures where a finite risk of cerebrovascular damage exists.

  N-取代的α-氨基酸及其衍生物被描述，以及用于制备和药物组合物的方法，这些方法在选择性阻断哺乳动物的N-甲基-D-天门冬氨酸(NMDA)兴奋性氨基酸受体方面是有用的，在治疗脑血管疾病如脑梗塞或脑梗塞、脑动脉痉挛、低血糖、心脏骤停、癫痫状态和脑外伤以及治疗精神分裂症、癫痫、神经退行性疾病、阿尔茨海默病或亨廷顿病方面也有用，并可作为外科手术中的麻醉剂，其中存在有限的脑血管损伤风险。
• US5179085A
  申请人：——

  公开号：US5179085A

  公开（公告）日：1993-01-12
• Exploration of N-phosphonoalkyl-, N-phosphonoalkenyl-, and N-(phosphonoalkyl)phenyl-spaced .alpha.-amino acids as competitive N-methyl-D-aspartic acid antagonists
  作者：Christopher F. Bigge、Graham Johnson、Daniel F. Ortwine、James T. Drummond、Daniel M. Retz、Laura J. Brahce、Linda L. Coughenour、Frank W. Marcoux、Albert W. Probert

  DOI：10.1021/jm00086a005

  日期：1992.4

  A series of N-substituted alpha-amino acids containing terminal phosphonic acid groups has been synthesized as potential N-methyl-D-aspartate (NMDA) receptor antagonists. NMDA receptor affinity was determined by displacement of a known ligand ([H-3]CPP) from crude rat brain synaptic membranes; an antagonist action was demonstrated by the inhibition of glutamate-induced accumulation of [Ca-45(2+)] in cultured rat cortical neurons. Receptor affinity was significantly correlated with antagonist activity (Figure 1). Moderate affinity (IC50 = 1-2-mu-M) was retained for analogues (31 and 32, Table 1; and 59 and 66, Table II) with reduced flexibility in their phosphonate side chains and is consistent with entropy playing a role in determining receptor affinity. Modeling studies suggest a folded conformation that brings the distal phosphonic acid group into close proximity with the alpha-carboxylate is required for binding. Each of the active analogues possess entropy-limiting features (double bonds, phenyl rings) in their side chains that allows the superposition of their key NH2, alpha-COOH, and distal PO3H2 groups with those of known competitive antagonists. Affinity decreased for analogues with alpha-carbon substitution, presumably because the alpha-substituent inhibits the folding of these structures into a bioactive conformation and occupies receptor-excluded volume. A complete description of the NMDA antagonist pharmacophore model is provided in a companion paper. 1